Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: therapeutic antibody fragments - Kuur Therapeutics

Next Previous
Drug Profile

Research programme: therapeutic antibody fragments - Kuur Therapeutics

Alternative Names: DLX-1008; DLX-212; DLX-2201; DLX-2681; DLX-2751; DLX-2882/3003; DLX-521; DLX-903; DLX-903/1008

Latest Information Update: 11 May 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Delenex Therapeutics
  • Developer Kuur Therapeutics
  • Class Antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors; Anaplastic lymphoma kinase inhibitors; Interleukin 1 beta inhibitors; Interleukin 12 inhibitors; Interleukin 17 inhibitors; Interleukin 23 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acne; Cancer; Glioblastoma; Gout; Hidradenitis suppurativa; Inflammatory bowel diseases; Kaposi's sarcoma; Neurological disorders; Psoriasis; Pyoderma; Skin disorders

Most Recent Events

  • 04 May 2021 Kuur Therapeutics has been acquired by Athenex
  • 10 Mar 2020 Cell Medica is now called Kuur Therapeutics
  • 28 Nov 2019 No recent reports of development identified for preclinical development in Acne in Switzerland (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top